Skip to main content
PharmaSGP Holding SE logo

PharmaSGP Holding SE — Investor Relations & Filings

Ticker · PSG ISIN · DE000A2P4LJ5 LEI · 3912005CZ12PVVCIPT91 F Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2023-05-02 Transaction in Own Shar…
Country DE Germany
Listing F PSG

About PharmaSGP Holding SE

https://pharmasgp.com/english/

PharmaSGP Holding SE is a pharmaceutical company specializing in the development and marketing of a broad portfolio of over-the-counter (OTC) drugs and other healthcare products. The company focuses on pharmacy-exclusive products for chronic indications, primarily utilizing natural active ingredients with a favorable side-effect profile. It holds a market-leading position in several therapeutic areas, particularly in systemic, chemical-free pain remedies with its RubaXX® (rheumatic pain) and Restaxil® (nerve pain) brand families. The portfolio also includes prominent brands such as Baldriparan® (natural sleep aid), Formigran® (migraine), Spalt® (general pain), and DESEO® and NERADIN® (sexual weakness).

Recent filings

Filing Released Lang Actions
Release of a capital market information
Transaction in Own Shares Classification · 100% confidence The document is a short announcement (3138 characters) dated May 2, 2023, titled 'Release of a capital market information'. It explicitly details the volume and weighted average price of shares bought back by PharmaSGP Holding SE between April 24 and April 28, 2023, referencing MAR regulations concerning share buybacks. This activity—the company purchasing its own stock—directly corresponds to the definition of 'Transaction in Own Shares'. Although it is a regulatory disclosure, the specific nature of the content (share repurchase details) makes 'POS' a more precise classification than the general 'RNS' fallback. It is not an announcement of a report, but a report of a transaction.
2023-05-02 English
Annual financial report 2022
Annual Report Classification · 100% confidence The document is a comprehensive annual report for PharmaSGP for the fiscal year 2022. It contains a detailed table of contents, management board forewords, a combined management report, consolidated financial statements, and an independent auditor's report. It is clearly the full annual report rather than an announcement or a summary. FY 2022
2023-04-28 English
Release of a capital market information
Transaction in Own Shares Classification · 100% confidence The document is titled 'Release of a capital market information' and explicitly details the volume and price of shares bought back by PharmaSGP Holding SE between April 17, 2023, and April 21, 2023, referencing MAR regulations concerning share buybacks. This activity—the company purchasing its own stock—directly corresponds to the definition of 'Transaction in Own Shares'. The document is a formal disclosure of this specific transaction, making the code 'POS' the most appropriate classification.
2023-04-24 English
Report Publication Announcement 2023
Report Publication Announcement Classification · 100% confidence The document is a short announcement (2263 characters) dated April 20, 2023, titled 'Preliminary announcement of the publication of financial reports'. It explicitly states that the 'Annual financial report' and 'Annual financial report of the group' will be disclosed on a future date (April 27, 2023) and provides links to where they will be available. According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report, rather than being the report itself, should be classified as a Report Publication Announcement (RPA).
2023-04-20 English
PharmaSGP plans dividend distribution of 49.2% after record year in 2022
Notice of Dividend Amount Classification · 99% confidence The document is a news release dated April 19, 2023, announcing that PharmaSGP Holding SE plans to propose a dividend distribution of 49.2% of net income to its shareholders at the upcoming Annual General Meeting (AGM). It also mentions the record financial results for FY 2022 and provides guidance for FY 2023. The core subject is the announcement of a dividend proposal related to shareholder returns. This aligns directly with the definition for 'Notice of Dividend Amount' (DIV). Although it mentions the AGM, the primary focus is the dividend amount itself, not the meeting materials (AGM-R) or the voting results (DVA). It is not a full financial report (10-K or IR) nor a general earnings release (ER), but a specific announcement about shareholder payout.
2023-04-19 English
Release of a capital market information
Transaction in Own Shares Classification · 100% confidence The document explicitly details the volume and weighted average price of shares bought back by PharmaSGP Holding SE during a specific period (April 10, 2023, to April 14, 2023), referencing EU regulations (MAR and Delegated Regulation (EU) No 2016/1052) related to share repurchase programs. This activity—the company purchasing its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. The document is a formal disclosure of this activity, not just an announcement of a report.
2023-04-17 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.